Strumento inattivo

Altre lingue NuGenerex Immuno-Oncology, Inc.

Azioni

NUGX

US67053X1028

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

NUGENEREX IMMUNO-ONCOLOGY, INC. : Changes in Control or Registrant, Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)	10/04/23
NUGENEREX IMMUNO-ONCOLOGY, INC. : Other Events (form 8-K)	23/07/21
NUGENEREX IMMUNO ONCOLOGY : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	14/06/21
Nugenerex Immuno-Oncology, Inc. Reports Earnings Results for the Third Quarter Ended April 30, 2021	14/06/21
NuGenerex Immuno-Oncology, Inc. has completed an IPO in the amount of $50.000004 million.	19/05/21
NUGENEREX IMMUNO-ONCOLOGY, INC. : Other Events (form 8-K)	27/04/21
NuGenerex Immuno-Oncology, Inc. Submits Protocol, Data, and Manufacturing Information to FDA in Advance of the IND Submission	12/04/21
NUGENEREX IMMUNO ONCOLOGY : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	12/03/21
Nugenerex Immuno-Oncology, Inc. Reports Earnings Results for the Second Quarter Ended January 31, 2021	12/03/21
Nugenerex Immuno-Oncology, Inc. and Generex Biotechnology Corporation Signs an Extension for the Receipt of the USD 5,000,000.00 Upfront Licensing Fee Payment	17/12/20
NuGenerex to Seek Merger or Acquisition Opportunities	15/12/20
Generex Biotechnology Corporation and Nugenerex Immuno-Oncology Grants Licensing Rights to Bintai Healthcare Sdn Bhd	25/11/20
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 Vaccine Partner Bintai Kinden Executes its Exclusive Distribution & Licensing Option for Australia and New Zealand	23/11/20
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology, Inc. Sign Distribution and Licensing Agreement with Bintai Healthcare SDN BHD	09/10/20
NuGenerex Immuno-Oncology Announces Closing of a Licensing & Distribution Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Global Markets	07/10/20
Bintai Healthcare Sdn Bhd Enters into A Distribution and Licensing Agreement with Generex Biotechnology Corporation and Its Majority Owned Subsidiary, Nugenerex Immuno-Oncology, Inc	06/10/20
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology, Inc. Sign Agreement with Bintai Kinden Corporation of Malaysia for the Development and Commercialization of the II-Key-SARS-CoV-2 Coronavirus Vaccine	24/09/20
NuGenerex Immuno-Oncology, Inc. has filed an IPO in the amount of $1 million.	14/09/20
Bintai Kinden Corporation Berhad Announces Memorandum of Understanding with Nugenerex Immuno-Oncology on New Business Opportunity (COVID-19 Vaccine)	17/08/20
Nugenerex Immuno-Oncology Closes $50 Million Financing Facility	15/07/20

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue NuGenerex Immuno-Oncology, Inc.

Azioni

NUGX

US67053X1028

Altre lingue

Filtri